These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27813427)

  • 1. Maintenance rituximab in Veterans with follicular lymphoma.
    Halwani AS; Rasmussen KM; Patil V; Morreall D; Li C; Yong C; Burningham Z; Dawson K; Masaquel A; Henderson K; DeLong-Sieg E; Sauer BC
    Cancer Med; 2020 Oct; 9(20):7537-7547. PubMed ID: 32860335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
    Davies A; Trask P; Demeter J; Florschütz A; Hänel M; Kinoshita T; Pettengell R; Quach H; Robinson S; Sadullah S; Sancho JM; Udvardy M; Witzens-Harig M; Knapp A; Liu W
    Ann Hematol; 2020 Dec; 99(12):2837-2846. PubMed ID: 32314038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
    Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
    Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformed lymphoma: what should I do now?
    Smith S
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):306-311. PubMed ID: 33275671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
    Thanarajasingam G; Leonard JP; Witzig TE; Habermann TM; Blum KA; Bartlett NL; Flowers CR; Pitcher BN; Jung SH; Atherton PJ; Tan A; Novotny PJ; Dueck AC
    Lancet Haematol; 2020 Jun; 7(6):e490-e497. PubMed ID: 32470440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
    Laurent C; Flores M; Chartier L; Huet S; Bolen CR; Venstrom JM; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Tesson B; Salles G; Morschhauser F; Xerri L
    Br J Haematol; 2023 Aug; 202(3):686-689. PubMed ID: 37218065
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature.
    Juárez-Salcedo LM; Conde-Royo D; Quiroz-Cervantes K; Dalia S
    Drugs Context; 2020; 9():. PubMed ID: 32426017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aggravating fury rituximab obliterated.
    Mahadevia H; Al-Obaidi A; Cossor F
    Haematologica; 2024 Jun; 109(6):2016-2018. PubMed ID: 38268447
    [No Abstract]   [Full Text] [Related]  

  • 10. Indolent NK-cell lymphoproliferative disorder of the GI tract: a rare indolent neoplasm of the GI tract.
    Attieh M; Asakrah S
    Blood; 2023 Apr; 141(16):2033. PubMed ID: 37079328
    [No Abstract]   [Full Text] [Related]  

  • 11. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
    Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pros and cons of rituximab maintenance in follicular lymphoma.
    Zhang L; Ghielmini M; Cheson BD; Ujjani C
    Cancer Treat Rev; 2017 Jul; 58():34-40. PubMed ID: 28628883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Moccia AA; Zucca E; Ghielmini M
    Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
    Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
    Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
    Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies.
    Milunović V; Bogeljić Patekar M; Jakubac KM; Mandac Rogulj I; Radić-Krišto D; Planinc-Peraica A; Ostojić Kolonić S
    Acta Clin Croat; 2017 Mar; 56(1):143-156. PubMed ID: 29120553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.
    Prica A; Crump M
    Leuk Lymphoma; 2019 Mar; 60(3):573-582. PubMed ID: 30668192
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.